Abstract: Reaction compositions are disclosed herein comprising at least water, beta-glucose -1-phosphate (beta-G1P), an acceptor molecule, and an alpha-1,3-glucan phosphorylase enzyme. These reactions can synthesize oligosaccharides and polysaccharides with alpha-1,3 glycosidic linkages. Further disclosed are alpha-1,3-glucan phosphorylase enzymes and methods of use thereof.

Abstract: An object of the present invention is to provide a soluble RNA-binding protein having high binding ability. The present invention provides an RNA-binding protein having an amino acid sequence represented by R1?-R1X—R2X—(R5X or R6Y)L-(R5X—R6Y)M-(R5X or R6Y)N—R7X—R8X—R8? wherein each symbol means an amino acid sequence recited in the specification.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: Disclosed are mutated phosphotriesterase enzymes with improved stability and activity, as well as their use in particular for degrading organophosphorus compounds.

Abstract: The present invention relates to polypeptide variants and methods for obtaining variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: Sialic acid recognizing-affinity reagents engineered from the neuraminidase NanB have lectin-like properties and defined specificities for sialic acid.

Abstract: The invention relates to a polypeptide comprising or consisting of the polypeptide of SEQ ID NO: 1 wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine, or a functionally equivalent variant of said polypeptide wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine and their use in medicine, particularly in the prevention and/or treatment of cancer.

Abstract: The present disclosure relates to a vector pair for screening TDP-43 (TAR DNA-binding protein 43 or TransActive Response DNA-binding protein 43) oligomer formation, a cell line transfected with the vector pair, and a method of monitoring TDP-43 oligomer formation using the cell line. More specifically, the vector pair includes: a first vector including a first TDP-43 gene and a first fluorescence protein gene; and a second vector including a second TDP-43 gene and a second fluorescence protein gene, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first TDP-43 gene and a protein expressed from the second TDP-43 gene. The vector pair is effective in that it makes it possible to monitor TDP-43 oligomer formation in living cells.

Abstract: The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.

Abstract: Engineered protein electron carriers, microorganisms expressing the same, and methods detecting regulated electron flow are described.

Abstract: The present invention relates to a composition for degrading prion material comprising a Thermitase. Such compositions may be formed in solution and are particularly suited to degrading prion material on medical equipment or in the environment due to the Thermitases mild pH range and activity at relatively low temperatures. The present invention also relates to novel proteases, methods for prion degradation, decontamination or disinfection and a kit of parts.

Abstract: The present invention relates to compositions such as cleaning compositions comprising a mix of enzymes. The invention further relates, use of compositions comprising such enzymes in cleaning processes and/or for deep cleaning of organic soiling, methods for removal or reduction of components of organic matter.

Abstract: The present application provides genetically modified yeast cell comprising an active succinate fermentation pathway, as well as methods of using these cells to produce succinate.

Abstract: The present disclosure relates to human porphobilinogen deaminase derived proteins and polynucleotides and methods of using these proteins and polynucleotides.

Abstract: It is intended to provide a fusion polypeptide that regulates the transcription of a target gene. The present inventors have provided a fusion polypeptide comprising: a cell-penetrating peptide; a DNA-binding polypeptide; and a transcriptional regulator.

Abstract: The invention includes methods for identifying polymerases, such as modified terminal nucleotidyl transferases (TdT), that are capable of binding nucleotides comprising removable 3?-O-blocking moieties to a nucleic acid initiator, without the use of a template. The invention further includes the identified polymerases, and methods of using the polymerases for de novo synthesis of predetermined oligonucleotide sequences.

Abstract: The present disclosure provides methods for utilizing genetically modified microbes to co-produce 3-hydroxypropionic acid (3-HP) and acetyl-CoA, and derivatives thereof from malonate semialdehyde as a common single intermediate. The disclosure further provides modified microbe that co-produce the 3-HP and acetyl-CoA derivatives from malonate semialdehyde.

Abstract: The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.

Abstract: The present invention refers to a protein-stabilized metal nanocluster comprising a variant of the helix A of the CTPR. It is also related to its uses for delivering of a drug, for interfering a metabolic reaction, for catalyzing a chemical reaction, as biocatalyst, for detecting an analyte, for phasing crystallographic data set, for cell labeling, for specific protein labeling, as biosensor, as a temperature sensor, as photosensitizer, or for the manufacture of an optoelectronic device.

Abstract: The present invention provides amino acid sequences of engineered decarboxylase polypeptides that are useful for catalyzing the decarboxylation of L-aspartate to produce ?-alanine, and the preparation process of engineered decarboxylase polypeptides as well as reaction process under industrial-relevant conditions. The present disclosure also provides polynucleotide sequences encoding engineered decarboxylase polypeptides, engineered host cells capable of expressing engineered decarboxylase polypeptides, and methods of producing ?-alanine using the engineered cells. Compared to the wild-type decarboxylase, the engineered decarboxylase polypeptide provided by the invention has better activity and stability, and overcomes the inhibition by L-aspartic acid and/or ?-alanine. The use of the engineered polypeptides of the present invention for the preparation of ?-alanine results in higher unit activity, lower cost, and has good industrial application prospects.